SCIMED, officially known as SCIMED Life Sciences, is a prominent player in the biotechnology industry, headquartered in the United States. Founded in 2010, the company has established itself as a leader in developing innovative medical devices and diagnostic solutions, primarily serving the healthcare sector across North America and Europe. SCIMED's core offerings include advanced imaging systems and precision instruments that enhance clinical outcomes and streamline workflows. What sets SCIMED apart is its commitment to integrating cutting-edge technology with user-friendly designs, ensuring that healthcare professionals can deliver optimal patient care. With a strong market position, SCIMED has achieved significant milestones, including numerous patents and partnerships with leading healthcare institutions. The company continues to drive advancements in medical technology, solidifying its reputation as a trusted name in life sciences.
How does SCIMED's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
SCIMED's score of 91 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SCIMED, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The organisation is a current subsidiary of Boston Scientific Scimed, Inc., which means that any emissions data or climate commitments would be inherited from its parent company, Boston Scientific Corporation. As part of its climate commitments, SCIMED aligns with the sustainability initiatives of Boston Scientific Corporation, which includes participation in various climate-related frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for SCIMED have not been disclosed. Given the lack of direct emissions data and specific reduction initiatives, SCIMED's climate strategy appears to be integrated within the broader commitments of its parent company. This context highlights the importance of corporate family relationships in understanding the environmental impact and sustainability efforts of subsidiaries like SCIMED.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SCIMED is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.